Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 960.05 INR 0.49% Market Closed
Market Cap: 369.7B INR
Have any thoughts about
Ajanta Pharma Ltd?
Write Note

Intrinsic Value

The intrinsic value of one AJANTPHARM stock under the Base Case scenario is 1 831.68 INR. Compared to the current market price of 2 960.05 INR, Ajanta Pharma Ltd is Overvalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AJANTPHARM Intrinsic Value
1 831.68 INR
Overvaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ajanta Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AJANTPHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AJANTPHARM?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Ajanta Pharma Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ajanta Pharma Ltd

Provide an overview of the primary business activities
of Ajanta Pharma Ltd.

What unique competitive advantages
does Ajanta Pharma Ltd hold over its rivals?

What risks and challenges
does Ajanta Pharma Ltd face in the near future?

Has there been any significant insider trading activity
in Ajanta Pharma Ltd recently?

Summarize the latest earnings call
of Ajanta Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ajanta Pharma Ltd.

Provide P/S
for Ajanta Pharma Ltd.

Provide P/E
for Ajanta Pharma Ltd.

Provide P/OCF
for Ajanta Pharma Ltd.

Provide P/FCFE
for Ajanta Pharma Ltd.

Provide P/B
for Ajanta Pharma Ltd.

Provide EV/S
for Ajanta Pharma Ltd.

Provide EV/GP
for Ajanta Pharma Ltd.

Provide EV/EBITDA
for Ajanta Pharma Ltd.

Provide EV/EBIT
for Ajanta Pharma Ltd.

Provide EV/OCF
for Ajanta Pharma Ltd.

Provide EV/FCFF
for Ajanta Pharma Ltd.

Provide EV/IC
for Ajanta Pharma Ltd.

Show me price targets
for Ajanta Pharma Ltd made by professional analysts.

What are the Revenue projections
for Ajanta Pharma Ltd?

How accurate were the past Revenue estimates
for Ajanta Pharma Ltd?

What are the Net Income projections
for Ajanta Pharma Ltd?

How accurate were the past Net Income estimates
for Ajanta Pharma Ltd?

What are the EPS projections
for Ajanta Pharma Ltd?

How accurate were the past EPS estimates
for Ajanta Pharma Ltd?

What are the EBIT projections
for Ajanta Pharma Ltd?

How accurate were the past EBIT estimates
for Ajanta Pharma Ltd?

Compare the revenue forecasts
for Ajanta Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ajanta Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ajanta Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ajanta Pharma Ltd compared to its peers.

Compare the P/E ratios
of Ajanta Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Ajanta Pharma Ltd with its peers.

Analyze the financial leverage
of Ajanta Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Ajanta Pharma Ltd.

Provide ROE
for Ajanta Pharma Ltd.

Provide ROA
for Ajanta Pharma Ltd.

Provide ROIC
for Ajanta Pharma Ltd.

Provide ROCE
for Ajanta Pharma Ltd.

Provide Gross Margin
for Ajanta Pharma Ltd.

Provide Operating Margin
for Ajanta Pharma Ltd.

Provide Net Margin
for Ajanta Pharma Ltd.

Provide FCF Margin
for Ajanta Pharma Ltd.

Show all solvency ratios
for Ajanta Pharma Ltd.

Provide D/E Ratio
for Ajanta Pharma Ltd.

Provide D/A Ratio
for Ajanta Pharma Ltd.

Provide Interest Coverage Ratio
for Ajanta Pharma Ltd.

Provide Altman Z-Score Ratio
for Ajanta Pharma Ltd.

Provide Quick Ratio
for Ajanta Pharma Ltd.

Provide Current Ratio
for Ajanta Pharma Ltd.

Provide Cash Ratio
for Ajanta Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Ajanta Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Ajanta Pharma Ltd?

What is the current Free Cash Flow
of Ajanta Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ajanta Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ajanta Pharma Ltd

Current Assets 27.9B
Cash & Short-Term Investments 7.6B
Receivables 10.4B
Other Current Assets 9.9B
Non-Current Assets 20B
Long-Term Investments 340m
PP&E 17.9B
Intangibles 133.2m
Other Non-Current Assets 1.7B
Current Liabilities 9.1B
Accounts Payable 4.2B
Other Current Liabilities 4.9B
Non-Current Liabilities 2B
Long-Term Debt 215.4m
Other Non-Current Liabilities 1.8B
Efficiency

Earnings Waterfall
Ajanta Pharma Ltd

Revenue
44.9B INR
Cost of Revenue
-10.9B INR
Gross Profit
34B INR
Operating Expenses
-22.7B INR
Operating Income
11.3B INR
Other Expenses
-2.6B INR
Net Income
8.8B INR

Free Cash Flow Analysis
Ajanta Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Ajanta Pharma reports robust financial growth, with Q2 revenue rising 15% to INR 1,187 crores. The company boasts a 14% H1 increase, driven by a 19% surge in Branded Generics. Gross margins improved to 77%, with EBITDA margins expected to hover around 28% for FY 2025. Guidance signals low-teens growth, with U.S. Generics anticipated at mid-single digits, while African operations anticipate mid-teens. PAT exhibited an 11% growth in Q2 and 15% in H1. The firm has strategically added 200 medical representatives to boost market presence, emphasizing a strong commitment to sustainable growth.

What is Earnings Call?
Fundamental Scores

AJANTPHARM Profitability Score
Profitability Due Diligence

Ajanta Pharma Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive 3-Year Average ROIC
67/100
Profitability
Score

Ajanta Pharma Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

AJANTPHARM Solvency Score
Solvency Due Diligence

Ajanta Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Negative Net Debt
97/100
Solvency
Score

Ajanta Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AJANTPHARM Price Targets Summary
Ajanta Pharma Ltd

Wall Street analysts forecast AJANTPHARM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AJANTPHARM is 3 019.71 INR with a low forecast of 2 000.81 INR and a high forecast of 3 848.25 INR.

Lowest
Price Target
2 000.81 INR
32% Downside
Average
Price Target
3 019.71 INR
2% Upside
Highest
Price Target
3 848.25 INR
30% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AJANTPHARM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AJANTPHARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AJANTPHARM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

369.7B INR

Dividend Yield

1.82%

Description

Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,234 full-time employees. The company went IPO on 2000-06-05. The Company’s marketing network operates in domestic and international markets. The firm produces a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market it is present in. The branded generics business is spread in India and approximately 30 emerging countries across Africa, South-East Asia, West Asia, and The Commonwealth of Independent States (CIS). The company has product portfolio includes complex technology products. The firm has also made substantial investments in its research and development (R&D) facilities.

Contact

MAHARASHTRA
Mumbai
Ajanta House,, Charkop, Kandivli West,
+912266061000
www.ajantapharma.com

IPO

2000-06-05

Employees

7 234

Officers

MD & Executive Director
Mr. Yogesh Mannalal Agrawal M.B.A
Joint MD & Director
Mr. Rajesh Mannalal Agrawal M.B.A
Executive Vice Chairman of the Board
Mr. Madhusudan Bhagwandas Agrawal B.Sc
Chief Financial Officer
Mr. Arvind K. Agrawal B Com, F.C.A, L.L.B
Senior VP of Legal, VP of Corporate Affairs, Company Secretary & Compliance Officer
Mr. Gaurang Chinubhai Shah
President of Tech & Operations
Mr. H. Satish Agrawal M Pharm
Show More
Senior Vice President of HR
Mr. Thampy Jacob
President of International Business
Mr. H. Nandkishore Agrawal
Deputy General Manager of Sustainability
Mr. Pankaj Barbind
Executive Vice President
Mr. Jagdish Dwarkadas Joshi
Show Less

See Also

Discover More
What is the Intrinsic Value of one AJANTPHARM stock?

The intrinsic value of one AJANTPHARM stock under the Base Case scenario is 1 831.68 INR.

Is AJANTPHARM stock undervalued or overvalued?

Compared to the current market price of 2 960.05 INR, Ajanta Pharma Ltd is Overvalued by 38%.

Back to Top